

SULFATED CCR5 PEPTIDES FOR HIV-1 INFECTION

Abstract of the Disclosure

This invention provides a compound comprising the structure:  $\Theta\alpha YDIN\gamma TS\beta\lambda$  wherein each T represents a threonine, each S represents a serine, each Y represents a tyrosine; each D represents an aspartic acid, each I represents an isoleucine; and each N represents an asparagine; wherein  $\alpha$  represents from 0 to 9 amino acids, with the proviso that if there are more than 2 amino acids, they are joined by peptide bonds in consecutive order and have a sequence identical to the sequence set forth in SEQ ID NO: 1 beginning with the I at position 9 and extending therefrom in the amino terminal direction; wherein  $\beta$  represents from 0 to 14 amino acids, with the proviso that if there are more than 2 amino acids, they are joined by peptide bonds in consecutive order and have a sequence identical to the sequence set forth in SEQ ID NO: 1 beginning with the E at position 18 and extending therefrom in the carboxy terminal direction; wherein  $\Theta$  represents an amino group or an acetylated amino group; wherein  $\lambda$  represents a carboxyl group or an amidated carboxyl group; wherein all of  $\alpha, Y, D, I, N, Y, Y, T, S$  and  $\beta$  are joined together by peptide bonds; further provided that at least two tyrosines in the compound are sulfated.